FDA Approved Stem Cell Treatments


FDA-Approved Treatments

The immediate appeal of Americord’s services lies in the amazing strides physicians and scientists have made since the first successful stem cell transplant. There are now over 80 medical conditions that can be treated with the hematopoietic stem cells (HSCs) collected from cord blood.

Approved Treatments 528x339 - Uses


  • Acute Leukemia
  • Acute Lymphoblastic Leukemia (ALL)
  • Acute Myelogenous Leukemia (AML)
  • Acute Biphenotypic Leukemia
  • Acute Undifferentiated Leukemia
  • Chronic Myelogenous Leukemia (CML)
  • Chronic Lymphocytic Leukemia (CLL)
  • Juvenile Chronic Myelogenous Leukemia (JCML)
  • Juvenile Myelomonocytic Leukemia (JMML)

Myelodysplastic Syndromes (sometimes called pre-leukemia)

  • Refractory Anemia
  • Refractory Anemia with Ringed Sideroblasts (Sideroblastic Anemia)
  • Refractory Anemia with Excess Blasts
  • Refractory Anemia with Excess Blasts in Transformation
  • Chronic Myelomonocytic Leukemia (CMML)


  • Hodgkin’s Lymphoma
  • Non-Hodgkin’s Lymphoma (Burkitt’s Lymphoma)

Other Disorders of Blood Cell Proliferation

  • Anemias
  • Aplastic Anemia
  • Congenital Dyserythropoietic Anemia
  • Fanconi Anemia
  • Paroxysmal Nocturnal Hemoglobinuria (PNH)

Inherited Red Cell Abnormalities

  • Sickle Cell Disease
  • Beta Thalassemia Major (Cooley’s Anemia)
  • Diamond-Blackfan Anemia
  • Pure Red Cell Aplasia

Inherited Platelet Abnormalities

  • Amegakaryocytosis / Congenital Thrombocytopenia
  • Glanzmann Thrombasthenia

Inherited Immune System Disorders

  • Severe Combined Immunodeficiency (SCID)
  • SCID with Adenosine Deaminase Deficiency (ADA-SCID)
  • SCID which is X-linked
  • SCID with absence of T & B Cells
  • SCID with absence of T Cells, Normal B Cells
  • Omenn Syndrome


  • Infantile Genetic Agranulocytosis (Kostmann Syndrome)
  • Myelokathexis


  • Ataxia-Telangiectasia
  • Bare Lymphocyte Syndrome
  • Common Variable Immunodeficiency
  • DiGeorge Syndrome
  • Hemophagocytic Lymphohistiocytosis
  • Leukocyte Adhesion Deficiency
  • Apraxia

Lymphoproliferative Disorders

  • Lymphoproliferative Disorder, X-linked (Epstein-Barr Virus Susceptibility)
  • Wiskott-Aldrich Syndrome

Myeloproliferative Disorders

  • Acute Myelofibrosis
  • Agnogenic Myeloid Metaplasia (Myelofibrosis)
  • Polycythemia Vera
  • Essential Thrombocythemia

Phagocyte Disorders

  • Chediak-Higashi Syndrome
  • Chronic Granulomatous Disease
  • Neutrophil Actin Deficiency
  • Reticular Dysgenesis
  • Multiple Myeloma
  • Plasma Cell Leukemia
  • Waldenstrom’s Macroglobulinemia
  • Cartilage-Hair Hypoplasia
  • Gunther’s Disease (Erythropoietic Porphyria)
  • Hermansky-Pudlak Syndrome
  • Shwachman-Diamond Syndrome
  • Systemic Mastocytosis

Transplants for Inherited Metabolic Disorders

  • Mucopolysaccharidoses (MPS) Storage Diseases
  • Hurler’s Syndrome (MPS-IH)
  • Scheie Syndrome (MPS-IS)
  • Hunter Syndrome (MPS-II)
  • Sanfilippo Syndrome (MPS-III)
  • Morquio Syndrome (MPS-IV)
  • Maroteaux-Lamy Syndrome (MPS-VI)
  • Sly Syndrome (MPS-VII) (Beta-Glucuronidase Deficiency)
  • Mucolipidosis II (I-cell Disease)

Leukodystrophy Disorders

  • Adrenoleukodystrophy (ALD)
  • Krabbe Disease (Globoid Cell Leukodystrophy)
  • Metachromatic Leukodystrophy
  • Pelizaeus-Merzbacher Disease

Lysosomal Storage Diseases

  • Niemann-Pick Disease
  • Sandhoff Disease
  • Wolman Disease

Inherited Disorders: Other

  • Lesch-Nyhan Syndrome
  • Osteopetrosis

Solid Tumors Not Originating in the Blood or Immune System

  • Neuroblastoma
  • Medulloblastoma

The Future of Stem Cell Treatments

Those who choose to invest in cord blood, cord tissue, and placental tissue banking are not just investing in the medicine of today—they are recognizing the future of stem cell and regenerative medicine.

The treatment potential of hematopoietic stem cells (HSCs) is far from exhausted. There are promising trials underway (over 1300 of them!) with these cells that have the potential to continue the revolution in treatment that began with the first successful stem cell transplants. Trials and tests are underway to address medical conditions such as:

  • Autism
  • Cerebral palsy
  • Diabetes
  • Multiple sclerosis (MS)
  • Autoimmune diseases like:
    • Lupus
    • Rheumatoid arthritis
    • Sarcoidosis

But the mesenchymal stem cells (MSCs) found in abundance in cord tissue and placental tissue are also the subject of serious research. Because these cells are capable of differentiating into multiple types of cells and tissues, including organ and muscle tissue, skin, bone, cartilage, and fat cells, many leading researchers and scientists believe that they will truly revolutionize medical practice.

MSC therapies have not been FDA-approved for treatment yet, but they have been approved for treatment in the European Union, Canada, and Australia and there are more than 300 major MSC clinical trials underway worldwide focusing on a wide range of medical conditions, including:

  • Heart disease
  • Injuries to bone and cartilage
  • Spinal cord injuries
  • Liver disease
  • Parkinson’s disease
  • Lung cancer
  • Type 1 diabetes
  • Stroke

At Americord, we are committed to partnering with physicians and scientists to help people live healthier, longer lives. It starts with our Executive Medical Director, leading hematologist, pediatric oncologist, and blood and stem cell banking expert Dr. Robert Dracker. Under his guidance, we are dedicated to stem cell banking innovations that will allow our customers to benefit from the great work being accomplished by researchers around the world.